We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hospital Capex Headwind: Temporary Setback or Lasting Risk for ISRG?
Read MoreHide Full Article
Key Takeaways
ISRG Q1 system placements rose 17% YoY, but international units fell due to CapEx tightening in key markets.
ISRG is expanding leasing, now over 50% of U.S. placements, to bypass hospital budget barriers.
ISRG saw 2% multiport and 26% SP utilization growth, aided by tools like Genesis and da Vinci 5 features.
Intuitive Surgical (ISRG - Free Report) entered 2025 with strong momentum — da Vinci system placements grew 17% year over year and procedures rose 17% globally in the first quarter. However, the company is encountering a growing challenge — capital expenditure (CapEx) constraints at hospitals, especially outside the United States.
While U.S. placements increased sharply (204 units vs. 148 last year), international placements declined slightly (163 vs. 165), with Japan, Germany and the United Kingdom flagged for tightening budgets. These pressures stem from post-COVID funding tapering, defense spending reallocation (in Europe) and policy reforms (in Japan & China). Management noted that although procedure growth remains robust in many early-stage markets like India and Taiwan, longer-term growth may be capped if CapEx constraints persist.
To mitigate CapEx friction, ISRG is expanding leasing and usage-based models (particularly in the United States), which now represent over 50% of placements. These models offer hospitals flexibility, bypassing the need for formal budget approvals. Still, their adoption in international markets remains nascent, and macro risks, including rising tariffs and interest rates, could amplify funding hurdles globally.
Meanwhile, ISRG is focusing on increasing utilization of its existing installed base, offering operational tools like Genesis and economic modeling support to help hospitals maximize returns. Notably, utilization grew 2% for multiport platforms and 26% for SP systems. The company is also banking on clinical differentiation, like force feedback in da Vinci 5, to build long-term demand and justify investment.
Hospital CapEx constraints are clearly impacting ISRG’s international system placements, but strategic levers, such as flexible financing, utilization support, and differentiated technology, offer near to mid-term buffers. Whether these measures can fully offset persistent funding headwinds, especially in Europe and Asia, will determine if the current drag is temporary or a structural hurdle to Intuitive’s global growth ambitions.
Competitor’s Take
Stryker (SYK - Free Report) reported no sign of slowdown in capital equipment demand, with first-quarter 2025 being its best-ever quarter for Mako installations globally. Management emphasized double-digit growth across capital-intensive businesses, supported by a robust order book and high system utilization, particularly in the orthopedic robotics sector.
Despite macro concerns, Stryker sees sustained strength in procedural volumes and customer interest in next-gen platforms like Mako 4, which features a smaller footprint and faster OR integration, addressing common CapEx objections. The company remains optimistic, citing no indicator of budget tightening and forecasting 8.5-9.5% organic sales growth for the year.
Medtronic (MDT - Free Report) acknowledged the impact of selective pressure in the hospital capital environment, but stressed stable U.S. purchasing trends and growth acceleration in emerging markets. The company continues to invest in its Hugo RAS platform, with FDA submission expected soon, positioning it to compete in robotic surgery without relying solely on high upfront CapEx.
MDT’s focus on value-based outcomes and procedural efficiency, such as in pulse field ablation and renal denervation, resonates with financially constrained systems. CEO Geoff Martha stated that Medtronic’s innovation pipeline (including closed-loop neurostimulators and AI-enabled spine platforms) is expanding the total addressable market while balancing spend and margin expansion.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 1.9% in the year-to-date period compared with the industry’s decline of 9.5%.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 60.33, above the industry average. But, it is still lower than its five-year median of 72.36. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies a 6.8% rise from the year-ago period’s level.
Image: Shutterstock
Hospital Capex Headwind: Temporary Setback or Lasting Risk for ISRG?
Key Takeaways
Intuitive Surgical (ISRG - Free Report) entered 2025 with strong momentum — da Vinci system placements grew 17% year over year and procedures rose 17% globally in the first quarter. However, the company is encountering a growing challenge — capital expenditure (CapEx) constraints at hospitals, especially outside the United States.
While U.S. placements increased sharply (204 units vs. 148 last year), international placements declined slightly (163 vs. 165), with Japan, Germany and the United Kingdom flagged for tightening budgets. These pressures stem from post-COVID funding tapering, defense spending reallocation (in Europe) and policy reforms (in Japan & China). Management noted that although procedure growth remains robust in many early-stage markets like India and Taiwan, longer-term growth may be capped if CapEx constraints persist.
To mitigate CapEx friction, ISRG is expanding leasing and usage-based models (particularly in the United States), which now represent over 50% of placements. These models offer hospitals flexibility, bypassing the need for formal budget approvals. Still, their adoption in international markets remains nascent, and macro risks, including rising tariffs and interest rates, could amplify funding hurdles globally.
Meanwhile, ISRG is focusing on increasing utilization of its existing installed base, offering operational tools like Genesis and economic modeling support to help hospitals maximize returns. Notably, utilization grew 2% for multiport platforms and 26% for SP systems. The company is also banking on clinical differentiation, like force feedback in da Vinci 5, to build long-term demand and justify investment.
Hospital CapEx constraints are clearly impacting ISRG’s international system placements, but strategic levers, such as flexible financing, utilization support, and differentiated technology, offer near to mid-term buffers. Whether these measures can fully offset persistent funding headwinds, especially in Europe and Asia, will determine if the current drag is temporary or a structural hurdle to Intuitive’s global growth ambitions.
Competitor’s Take
Stryker (SYK - Free Report) reported no sign of slowdown in capital equipment demand, with first-quarter 2025 being its best-ever quarter for Mako installations globally. Management emphasized double-digit growth across capital-intensive businesses, supported by a robust order book and high system utilization, particularly in the orthopedic robotics sector.
Despite macro concerns, Stryker sees sustained strength in procedural volumes and customer interest in next-gen platforms like Mako 4, which features a smaller footprint and faster OR integration, addressing common CapEx objections. The company remains optimistic, citing no indicator of budget tightening and forecasting 8.5-9.5% organic sales growth for the year.
Medtronic (MDT - Free Report) acknowledged the impact of selective pressure in the hospital capital environment, but stressed stable U.S. purchasing trends and growth acceleration in emerging markets. The company continues to invest in its Hugo RAS platform, with FDA submission expected soon, positioning it to compete in robotic surgery without relying solely on high upfront CapEx.
MDT’s focus on value-based outcomes and procedural efficiency, such as in pulse field ablation and renal denervation, resonates with financially constrained systems. CEO Geoff Martha stated that Medtronic’s innovation pipeline (including closed-loop neurostimulators and AI-enabled spine platforms) is expanding the total addressable market while balancing spend and margin expansion.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 1.9% in the year-to-date period compared with the industry’s decline of 9.5%.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 60.33, above the industry average. But, it is still lower than its five-year median of 72.36. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies a 6.8% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.